PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Friedreich ataxia

Drugs in development · updated 30 October 2026

Friedreich ataxia: drugs in development

Rare diseasePrevalence 1-9 / 100 000 according to Orphanet · ORPHA:95

As of 30 October 2026 there are 14 active clinical trials (recruiting or ongoing, phases I–III) on 9 drugs for friedreich ataxia. 7 are experimental, that is not yet approved in the United States.

14Active trials
7Experimental drugs
2Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
NomlabofuspCTI-1601III2NCT07778836
VatiquinoneIII2NCT07681713
DT-216P2I–II2NCT06874010
LX2006I–II2NCT05445323
GV101II1NCT07870590
ATI-105I1NCT07869654
SGT-212I1NCT07180355

Sorted by most advanced phase and number of active trials.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
OmaveloxoloneSkyclarys®III2NCT06953583
PrednisonePredinisone, CortancylI1NCT05302271

Sorted by most advanced phase and number of active trials.

All 9 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D005621 “Friedreich Ataxia”. Prevalence: Orphanet.

ItalianoFrançaisDeutsch